ArticleArthroplasty today2025
A Single Perioperative Dose of Dexamethasone Is Not Associated With an Increased Risk of Infection in Patients With Hip or Knee Osteoarthritis Considered for Elective Primary Total Hip or Total Knee Arthroplasty.
Article in Arthroplasty today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Perioperative dexamethasone administration has been associated with reduced postoperative nausea, pain, and enhanced recovery after total hip (THA) and knee arthroplasty (TKA). However, there is ongoing concern about the influence of glucocorticoids on periprosthetic joint infection (PJI) due to the high heterogeneity of available studies. The present study aimed to evaluate the effect of perioperative dexamethasone use on early and delayed PJI after THA and TKA in patients with primary osteoarthritis. Methods: A consecutive cohort of patients from a single teaching hospital were analyzed. For each procedure, the intravenous application of 0.15 mg/kg dexamethasone in a single dose perioperatively was recorded. Additionally, patient characteristics, joint affected and the revision surgery due to infection after primary surgery were collected from the hospital registry and medical records. All patients with revision surgery for PJI were subjected to the standard protocol of perioperative diagnostics. Results: Between 2017 and 2023, a total of 8905 procedures were included, 1318 with perioperative dexamethasone application and 7587 without. The patients who received perioperative dexamethasone (dexa group) were similar in age (effect size (ES) = 0.03), sex (ES = 0.002), body mass index (ES = 0.06) and American Society of Anaesthesiologists score (ES = 0.06) compared to patients who did not (non-dexa group). In total, 54 PJIs were observed, 6 of them were in dexamethasone and 48 in the non-dexamethasone group. Multivariate logistic regression showed that the use of dexamethasone was not associated with higher odds for PJI within the first 2 postoperative years (odds ratio 0.80 95% confidence interval 0.30-1.73; Conclusions: Our study is the first single-dose, single-hospital study with standardized PJI diagnostic procedures at revision surgery, which shows that perioperative intravenous dexamethasone has no association with an increased risk of early or delayed PJI in THA and TKA in patients with primary osteoarthritis. The present data provide evidence in support of the perioperative administration of a single dose of dexamethasone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.